A field team needs new content to take into the field that is not always about a product. Providing useful data in a quick format helps busy professionals.
When an MSL is planning for a KOL meeting, topics for discussion are not the only consideration. The MSL should also consider how the dialogue will develop through the give and take of conversation. By considering potential KOL responses, the MSL can be prepared with data points, articles, slides, and verbiage to drive the conversation to a successful conclusion.
The FDA issued new draft guidance last Friday along with a press release. Did you notice it?
No, not the one about biosimilars or off-label HEOR discussions. This guidance has the following title: ‘Indications and Usage Section of Labeling for Human Prescription Drug and biological Products – Content and Format.’ 
It is a mouthful, right?
The intent is to provide more concise and explicit descriptions of the conditions and populations for a specific drug indication. I had visions of infographic style labeling with clear and large icons to make scanning the document more accessible for clinicians (and the occasional patient that reads them). Nope. That is not where this is going.